Boehringer Ingelheim Corporation Release: Benefits of Pradaxa® Maintained in Difficult to Treat Patients With Atrial Fibrillation and Symptomatic Heart Failure

Published: Jul 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Published in the European Journal of Heart Failure1, results from a new sub-analysis of the RE-LY®i trial demonstrate important benefits of Pradaxa® (dabigatran etexilate) over warfarin in difficult-to-treat patients with non-valvular atrial fibrillation (AF) and previous symptomatic heart failure (HF). The outcomes in heart failure patients were consistent with the results from the main RE-LY® trial: Pradaxa® 150mg twice daily reduced the risk of stroke including ischaemic stroke with similar rates of major bleeding compared to warfarin and Pradaxa® 110mg twice daily showed similar rates of stroke but significantly reduced major bleeding compared to warfarin. Importantly, both doses of Pradaxa® significantly reduced intracranial as well as total bleeding.1,2,3

Help employers find you! Check out all the jobs and post your resume.

Back to news